Animal models of established breast cancer have demonstrated that VDR agonists can reduce tumor growth (and in some cases trigger tumor regression) with minimal effects on calcemia [the most common and dangerous side effect of 1,25(OH)2D3 therapy]. Here, VDR is linked to breast cancer.